SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to Earnings Call for financial results for the first quarter ending June 30, 2021. Sun Pharmaceutical Industries Ltd - 524715 - Board Meeting Intimation for Inter Alia Consideration And Approval Of Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2021
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2021 ,inter alia, to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2021
Sun Pharmaceutical Industries Q1 PAT seen up 17.5% YoY to Rs 1,346.7 cr: KRChoksey
Net Sales are expected to increase by 12.7 percent Y-o-Y (up 0.3 percent Q-o-Q) to Rs 8,547.7 crore, according to KRChoksey. Sun Pharmaceutical Industries Ltd - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 10, 2021 for Shanghvi Finance Pvt Ltd Sun Pharmaceutical Industries Ltd - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 10, 2021 for Raksha Sudhir Valia SPARC raises 1,112 cr via warrants
The committee of board of Sun Pharma Advanced Research Company has approved the allotment of about 6.25 crore warrants on preferential basis at 178 e Sun Pharmaceutical Industries Ltd - 524715 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, please find enclosed certificate dated July 6, 2021 for the quarter ended June 30, 2021 received from M/s. Link Intime (India) Private Limited, Registrar & Share Transfer Agent of the Company. Sun Pharmaceutical Industries Ltd - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to the launch of 'Sunkalp' on the occasion of National Doctors' Day, which we shall be releasing after sending this letter to you.